Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer Clinical Trial

Official title:

Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02241551
• Other study ID #: UPCI 13-143
• Status: Terminated
• Phase: Phase 2
• Start date: December 2014
• Est. completion date: March 3, 2017

Study information

• Verified date: June 2018
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and nab-paclitaxel. After three cycles of treatment in the gemcitabine/nab-paclitaxel arm and 6 cycles in the mFOLFIRINOX arm, patients will be restaged with CT scans and if they remain borderline resectable or have improvement of their disease They will then proceed to SBRT followed by surgical resection.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: March 3, 2017
• Est. primary completion date: March 3, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

All patients must meet the following criteria within 28 days of randomization (unless otherwise indicated) to be enrolled in the protocol:

• Histologically or cytologically proven adenocarcinoma of the pancreas. If the patient has mixed tumor with predominant adenocarcinoma pathology, they can be enrolled.

• Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0 being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)

• The tumor must be deemed as being borderline resectable. Final CT confirmation of surgical staging/ eligibility will be at the discretion of the pancreatic surgeon of the patient.

• Disease is confined to locoregional site as confirmed by the CT and / or diagnostic staging laparoscopy to avoid occult peritoneal deposits. Diagnostic laproscopy will be only if absolutely required

• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT

• Screening Endoscopic ultrasound if done prior to consent but within 6 weeks of expected randomization date it may be used.

• Karnofsky performance status greater than or equal to 70 or Eastern Cooperative Oncology Group (ECOG) performance of 0-2.

• Age > 18

• Estimated life expectance > 12 weeks

• If female patient is of child bearing potential, she must have a negative serum pregnancy test (ßhCG) documented up to 72hrs prior to administration of first study drug

• Patient has screening blood work performed which includes the following (should be drawn = 14 days prior to randomization)

• absolute neutrophil count (ANC) > 1.5 x 109/L

• Platelet count = 100000/mm3

• Hemoglobin (HgB) = 9g/dL

• aspartate aminotransferase (AST),Alanine Aminotransferase (ALT)= 2.5 x upper limit of normal (ULN) Total Bilirubin = ULN

• Serum Cr within normal limits (WNL)

• Coagulation studies with Prothrombin Time and International Normalized Ratio (PT/INR) and partial thromboplastin time (PTT) within normal limits (±15%). • Patient has a urinalysis obtained (=14 days prior to randomization) and the results are deemed not clinically significant by the investigator.

• Patient has no evidence of jaundice at the time of enrolment. If stent is required to alleviate jaundice, it should be metallic. If patient has a previously placed stent and this is plastic, this should be changed to metallic.

• Patient's pain symptoms have remained stable with no adjustment to analgesics within 7 days prior to randomization. Patient must be able to swallow entreat medications with no requirement for a feeding tube. Patient's must not have intractable nausea or vomiting which prohibits the patient from oral medications

• Diabetes must be controlled prior to enrollment

• Disease must be encompassed in a reasonable SBRT "portal" as defined by the treating radiation oncologist

Exclusion Criteria:

• Ineligible Histology including non-adenocarcinomas, adenosquamous carcinoma, islet cell carcinomas, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct and ampullary carcinomas

• Evidence of distant metastasis on upright chest x-ray, CT or other staging studies

• Subjects with recurrent disease

• Prior radiation therapy to the upper abdomen or liver at the discretion of the treating radiation oncologist could impair delivery of the prescribed radiation treatment

• Prior chemotherapy

• Subjects in their reproductive age who are breast feeding or have a positive pregnancy test

• Any co-morbid condition of sufficient severity to limit full compliance with the protocol per assessment by the individual treating physician

• Concurrent active infection

• Previous or current malignancies of other histologies within the last 3 yrs prior to randomization; with the exception of cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer

• Patient with known historical or active infection with HIV, Hepatitis B or Hepatitis C

• Patient who has undergone recent major surgery, other than diagnostic surgical procedure within 4 weeks prior to randomization.

• Patient who has a history of allergy or hypersensitivity to any of the study drugs.

• Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies

• Patients with greater than 2 screening peripheral neuropathy.

Related Conditions & MeSH terms

• Borderline Resectable Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• gemcitabine/nab-paclitaxel
three cycles of treatment in the gemcitabine/nab-paclitaxel
• mFOLFIRINOX
6 cycles in the mFOLFIRINOX

Locations

Country	Name	City	State
United States	Hillman Cancer Center	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Nathan Bahary, MD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Efficacy Using Neo-adjuvant Gemcitabine Plus Nab-paclitaxel in Patients Receiving SBRT and Surgery for Borderline Resectable Pancreatic Cancer, Using Neo-adjuvant mFOLFIRINOX as a Control	Efficacy: pathological complete response (pCR) and R0 resection. Safety: Grade 4 toxicity.	up to 5 years
Secondary	R0 Resection Rates in Borderline Resectable Pancreatic Cancer		Up to 5 years
Secondary	Incidence of Grade 3 and 4 Toxicities for the 2 Chemotherapy Regimens That Occur After Cycle 1 Day 1	According to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTAE, v4.0)	Up to 5 years
Secondary	Ca19-9 Response to Neoadjuvant Chemotherapy		Up to 5 years
Secondary	Time to Disease Progression		Up to 5 years
Secondary	Measurement of Biomarkers (SPARC, RM1 and SMAD4) in Tissues	This wil be measured in tissues that are obtained at screening and in the resected tumour specimen	Up to 5 years
Secondary	Radiological Response Rate to Therapy	Radiological improvements will be evaluated by determining changes in density of measurable disease on CT scan pre and post chemotherapy	Up to 5 years
Secondary	Quality of Life Effects of Chemotherapy on Patients Receiving Chemotherapy and SBRT	This will be measured using the FACT-HB questionaire	Up to 5 years